<DOC>
	<DOCNO>NCT02951585</DOCNO>
	<brief_summary>Intra-articular hyaluronic acid injection , also know viscosupplementation , treatment option knee osteoarthritis serf restore decrease rheological property synovial fluid . KARTILAGE® CROSS visco-elastic gel highly purify reticulate hyaluronic acid . It contain mannitol provide anti-oxidative action avoid hyaluronic acid depolymerization . Reticulation mannitol increase residency time product joint cavity allow single injection painful knee osteoarthritis patient . The US food drug administration ( FDA ) European medicine agency ( EMA ) , recently publish guideline recommend high level integration biomarkers development test new drug advance decision-making dosing , time treatment effect , trial design , risk/benefit analysis . Biomarkers use process drug development , also future assessment individual patient 's response treatment . Several soluble biomarkers identify potential candidate predict monitor efficacy intervention . Coll2-1 , degradation product type II collagen , Coll2-1NO2 , nitrated form Coll2-1 peptide study human osteoarthritis enter qualification process . Evidences demonstrate pertinent foresee marker use diagnosis , prognosis , burden disease monitoring treatment efficacy . The aim study provide first kinetic data regard biomarkers painful knee osteoarthritis patient treat new reticulate hyaluronic acid . The effect treatment compare saline solution . The primary endpoint specific osteoarthritis biomarker , Coll2-1 . The secondary endpoint effect treatment placebo biomarkers osteoarthritis , clinical efficacy tolerance</brief_summary>
	<brief_title>Pilot , Prospective , Comparative Multicentric Study Evaluating Effects Arthrosis Biomarkers , Clinical Effectiveness , Tolerance Intra-articular Injection Hyaluronic Acid KARTILAGE CROSS Versus Placebo Patients Suffering From Knee Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Man Women , age 45 80 Presenting symptomatic femorotibial knee osteoarthritis respond clinical radiologic ACR ( American College Rheumatology ) criterion , Symptomatic since least 6 month Mean global knee pain determine Visual Analog Scale last 24 hour 40 mm ( without NSAIDs analgesic 48 hour ) . Kellgren Lawrence ( K &amp; L ) radiological stage must II III picture last less 12 month Requiring treatment hyaluronic acid failure intolerance first line analgesic NSAIDs Having sign informed consent receive comprehensive information Capable follow study instruction Benefiting health insurance . Related osteoarthritis pathology : Significant clinical knee effusion Radiographical Kellgren Lawrence grade I IV Osteoarthritis secondary microcrystalline arthropathy : chondrocalcinosis previously know defined calcium border least one tibiofemoral spacing , gout ... Isolated femoropatellar osteoarthritis Presence another joint ( evaluated knee ) affect osteoarthritis ( know symptomatic ) : collateral knee , hip , hand , shoulder , ankle foot Chondromatosis villonodular synovitis knee Paget disease Recent trauma ( &lt; 1 month ) evaluate knee Pathologies interfere evaluation osteoarthritis ( microcrystalline inflammatory arthropathy , rheumatoid arthritis , radiculalgia low limb , arteritis . etc ) Acute inflammatory osteoarthritis ( Kofus ≥ 7 ) Related previous concomitant treatment Corticosteroids injection last month injection regardless concern joint Hyaluronan injection last 6 month injection regardless concern joint Analgesics NSAIDs intake last 48 hour inclusion visit Change dosage slowacting drug arthrosis i.e . chondroitin , glucosamine , diacerein avocadosoybean unsaponifiables last 3 month inclusion plan study Arthroscopy surgery target knee last 3 month inclusion Oral corticotherapy Related associate pathology Severe disease ( severe hepatic failure , renal failure , uncontrolled cardiovascular diseases… . ) Dermatological infection site injection Anticoagulant treatment Risk hemorrhage accord evaluator injector assessment Related patient Known allergy hyaluronan Known allergy acetaminophen Known allergy mannitol Pregnant breastfeed woman Premenopausal woman without contraception Patient unable read , write Patient participate clinical research investigation last 3 month Patient guardianship judicial protection</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>